Synonyms: compound 32 [WO2019226977A1] [1]
Compound class:
Synthetic organic
Comment: Polvitolimod is classified as a toll-like receptor agonist in WHO proposed INN list 126 (January 2022). It was included in the 'COVID' section of that list. Patent mining suggests that polvitolimod is a TLR7 agonist prodrug, that was developed by Primmune Therapeutics as a potential treatment of cancer and infectious disease. In patent WO2019226977 polvitolimod's chemical structure matches that of Compound 32 [1]. Assessment of Primmune Therapeutics' pipeline indicates that polvitolimod is likely to be their clinical candidate PRTX007. If this is the correct name-to-structure association the active drug (PRX034) is likely to be compound 27 as claimed in the patent.
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
Is prodrug? | Yes |
Active form | compound 27 [WO2019226977A1] |
IUPAC Name ![]() |
2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one |
International Nonproprietary Names ![]() |
|
INN number | INN |
12239 | polvitolimod |
Synonyms ![]() |
|
compound 32 [WO2019226977A1] [1] |
Database Links ![]() |
|
CAS Registry No. | 2389988-81-0 (source: WHO INN record) |
GtoPdb PubChem SID | 461663428 |
PubChem CID | 151237987 |
Search Google for chemical match using the InChIKey | NPRYCHLHHVWLQZ-TURQNECASA-N |
Search Google for chemicals with the same backbone | NPRYCHLHHVWLQZ |
Search PubMed clinical trials | polvitolimod |
Search PubMed titles | polvitolimod |
Search PubMed titles/abstracts | polvitolimod |
UniChem Compound Search for chemical match using the InChIKey | NPRYCHLHHVWLQZ-TURQNECASA-N |
UniChem Connectivity Search for chemical match using the InChIKey | NPRYCHLHHVWLQZ-TURQNECASA-N |